{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:49:03Z","timestamp":1787168943245,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["SYMPATHY"],"award-info":[{"award-number":["SYMPATHY"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["CompLS project MOFA under grant agreement number 031L0171A"],"award-info":[{"award-number":["CompLS project MOFA under grant agreement number 031L0171A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB873"],"award-info":[{"award-number":["SFB873"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Else Kr\u00f6ner Fresenius Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1038\/s41375-022-01782-z","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T01:02:31Z","timestamp":1671670951000},"page":"465-472","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters"],"prefix":"10.1038","volume":"37","author":[{"given":"Peter-Martin","family":"Bruch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0648-1832","authenticated-orcid":false,"given":"Sascha","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Finel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Boumendil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2780-3300","authenticated-orcid":false,"given":"Hildegard","family":"Greinix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4049-7854","authenticated-orcid":false,"given":"Thomas","family":"Heinicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6052-2618","authenticated-orcid":false,"given":"Wolfgang","family":"Bethge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5050-220X","authenticated-orcid":false,"given":"Dietrich","family":"Beelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7070-487X","authenticated-orcid":false,"given":"Christoph","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6239-7387","authenticated-orcid":false,"given":"Luca","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Sch\u00e4fer-Eckart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Bittenbring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Finke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Sengeloev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1682-8657","authenticated-orcid":false,"given":"Mael","family":"Heiblig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Montoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"key":"1782_CR1","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1182\/blood-2002-10-3297","volume":"101","author":"M Herling","year":"2003","unstructured":"Herling M, Teitell MA, Shen RR, Medeiros LJ, Jones D. TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. Blood. 2003;101:5007\u20139.","journal-title":"Blood."},{"key":"1782_CR2","doi-asserted-by":"publisher","first-page":"4838","DOI":"10.1182\/bloodadvances.2020002474","volume":"4","author":"K Laribi","year":"2020","unstructured":"Laribi K, Baugier de Materre A, Sobh M, Cerroni L, Valentini CG, Aoki T, et al. Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients. Blood Adv. 2020;4:4838\u201348.","journal-title":"Blood Adv"},{"key":"1782_CR3","doi-asserted-by":"publisher","first-page":"4238","DOI":"10.1182\/bloodadvances.2019000647","volume":"3","author":"F Garnache-Ottou","year":"2019","unstructured":"Garnache-Ottou F, Vidal C, Biichle S, Renosi F, Poret E, Pagadoy M, et al. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? Blood Adv. 2019;3:4238\u201351.","journal-title":"Blood Adv"},{"key":"1782_CR4","doi-asserted-by":"publisher","first-page":"10174","DOI":"10.18632\/oncotarget.7101","volume":"7","author":"L Martin-Martin","year":"2016","unstructured":"Martin-Martin L, Almeida J, Pomares H, Gonzalez-Barca E, Bravo P, Gimenez T, et al. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy. Oncotarget. 2016;7:10174\u201381.","journal-title":"Oncotarget."},{"key":"1782_CR5","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1182\/blood.2019001144","volume":"134","author":"J Taylor","year":"2019","unstructured":"Taylor J, Haddadin M, Upadhyay VA, Grussie E, Mehta-Shah N, Brunner AM, et al. Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark. Blood 2019;134:678\u201387.","journal-title":"Blood"},{"key":"1782_CR6","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/sj.bmt.1704215","volume":"32","author":"P Reimer","year":"2003","unstructured":"Reimer P, Rudiger T, Kraemer D, Kunzmann V, Weissinger F, Zettl A, et al. What is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplant. 2003;32:637\u201346.","journal-title":"Bone Marrow Transplant"},{"key":"1782_CR7","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.bbmt.2010.12.706","volume":"17","author":"S Dietrich","year":"2011","unstructured":"Dietrich S, Andrulis M, Hegenbart U, Schmitt T, Bellos F, Martens UM, et al. Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients: results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity. Biol Blood Marrow Transplant. 2011;17:1250\u20134.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1782_CR8","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1182\/blood-2012-08-448613","volume":"121","author":"D Roos-Weil","year":"2013","unstructured":"Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E, et al. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2013;121:440\u20136.","journal-title":"Blood."},{"key":"1782_CR9","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1182\/blood-2015-01-621268","volume":"125","author":"T Aoki","year":"2015","unstructured":"Aoki T, Suzuki R, Kuwatsuka Y, Kako S, Fujimoto K, Taguchi J, et al. Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood. 2015;125:3559\u201362.","journal-title":"Blood."},{"key":"1782_CR10","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.clml.2018.07.295","volume":"18","author":"MA Kharfan-Dabaja","year":"2018","unstructured":"Kharfan-Dabaja MA, Reljic T, Murthy HS, Ayala E, Kumar A. Allogeneic hematopoietic cell transplantation is an effective treatment for blastic plasmacytoid dendritic cell neoplasm in first complete remission: systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2018;18:703\u20139.e1","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1782_CR11","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/bjh.14954","volume":"179","author":"MA Kharfan-Dabaja","year":"2017","unstructured":"Kharfan-Dabaja MA, Al Malki MM, Deotare U, Raj RV, El-Jurdi N, Majhail N, et al. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. Br J Haematol. 2017;179:781\u20139.","journal-title":"Br J Haematol"},{"key":"1782_CR12","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1182\/bloodadvances.2020001875","volume":"4","author":"S Yun","year":"2020","unstructured":"Yun S, Chan O, Kerr D, Vincelette ND, Idrees A, Mo Q, et al. Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant. Blood Adv. 2020;4:3435\u201342.","journal-title":"Blood Adv"},{"key":"1782_CR13","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1782_CR14","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.1182\/bloodadvances.2019000173","volume":"4","author":"N Pemmaraju","year":"2020","unstructured":"Pemmaraju N, Konopleva M. Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm. Blood Adv. 2020;4:4020\u20137.","journal-title":"Blood Adv"},{"key":"1782_CR15","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1182\/blood-2016-09-726653","volume":"129","author":"M Leclerc","year":"2017","unstructured":"Leclerc M, Peffault de Latour R, Michallet M, Blaise D, Chevallier P, Rohrlich PS, et al. Can a reduced-intensity conditioning regimen cure blastic plasmacytoid dendritic cell neoplasm? Blood. 2017;129:1227\u201330.","journal-title":"Blood."},{"key":"1782_CR16","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/bmt.2009.270","volume":"45","author":"P Kaloyannidis","year":"2010","unstructured":"Kaloyannidis P, Zomas A, Paterakis G, Vadikoliou C, Mallouri D, Sakkas L, et al. GVL effect in plasmacytoid DC leukemia\/lymphoma. Bone marrow Transplant. 2010;45:961\u20132.","journal-title":"Bone marrow Transplant"},{"key":"1782_CR17","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1097\/01.tp.0000286098.28481.7d","volume":"84","author":"R Ben Amor","year":"2007","unstructured":"Ben Amor R, Hicheri Y, Pautas C, Jouault H, Kuentz M, Cordonnier C, et al. Successful non-myeloablative allogeneic HLA-identical stem cell transplantation for CD4\/CD56 positive acute leukemia. Transplantation. 2007;84:1066\u20137.","journal-title":"Transplantation."},{"key":"1782_CR18","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","volume":"26","author":"A D\u2019Souza","year":"2020","unstructured":"D\u2019Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, et al. Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2020;26:e177\u2013e82.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1782_CR19","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","volume":"380","author":"N Pemmaraju","year":"2019","unstructured":"Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380:1628\u201337.","journal-title":"N Engl J Med"},{"key":"1782_CR20","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1158\/2159-8290.CD-16-0999","volume":"7","author":"J Montero","year":"2017","unstructured":"Montero J, Stephansky J, Cai T, Griffin GK, Cabal-Hierro L, Togami K, et al. Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax. Cancer Discov. 2017;7:156\u201364.","journal-title":"Cancer Discov"},{"key":"1782_CR21","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1200\/JCO.19.03011","volume":"38","author":"CS Hourigan","year":"2020","unstructured":"Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, et al. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2020;38:1273\u201383.","journal-title":"J Clin Oncol"},{"key":"1782_CR22","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3324\/haematol.2020.247569","volume":"106","author":"W Wang","year":"2021","unstructured":"Wang W, Khoury JD, Miranda RN, Jorgensen JL, Xu J, Loghavi S, et al. Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm. Haematologica. 2021;106:1047\u201355.","journal-title":"Haematologica."}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01782-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01782-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01782-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T06:11:34Z","timestamp":1675404694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01782-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1782"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01782-z","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]},"assertion":[{"value":"28 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PD: consultancy for AbbVie, AstraZeneca, Gilead, Janssen, Novartis, Riemser, Roche; speakers bureau for AbbVie, Gilead, Novartis, Riemser, Roche; research support from Neovii and Riemser. SD: consultancy for AbbVie, AstraZeneca, Gilead, Janssen, Novartis, Riemser, Roche; speakers bureau for AbbVie, Gilead, Novartis, Riemser, Roche; research support from Gilead and Janssen. P-MB: speakers bureau for AstraZeneca. TH: consultancy Eurocept, travel grants from Jazz, Gilead, Eurocept and Daichii. All other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}